Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Dysfunctions Associated with Pharmacological Treatment of Schizophrenia
2018-000178-31Phase 4Completed
- Sponsor
- FINBA
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of olanzapine and aripiprazole in schizophrenia (2 arms), sponsored by FINBA. Primary endpoint: Metabolic change induced by second generation antipsychotics. Started Mar 2018; status: completed.
02
Drugs
olanzapinearipiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2018-000178-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000178-31.